Inovio Biomedical Corporation (INO) Establishes Agreements with National Cancer Institute and International Aids Vaccine Initiative to Conduct Research Using Inovio's DNA Delivery Technology
7/24/2007 6:16:11 AM
SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today its wholly-owned subsidiary, Genetronics, Inc., has entered into separate collaboration agreements with two internationally recognized research organizations, the National Cancer Institute (NCI) and International Aids Vaccine Initiative (IAVI), to evaluate Inovio’s electroporation technology for the delivery of DNA vaccines. Inovio’s DNA delivery systems are designed with the aim of enhancing the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.
comments powered by